> Shanghai-based Phagelux has bought key assets of Wuhan-based Scithera Microbial Technologies that include multiple lysins and for the rapid development of lysin solutions as well as keeping current staff, who will be located in new Phagelux laboratory facilities at the BioLake Science Park in Wuhan. Release
> Australia's CSL said it would buy up to AU$1 billion of its shares from the market in addition to its regular program, making the announcement of its largest such program at an annual meeting of shareholders on Oct. 15. Release
> Hong Kong-listed Helius Medical Technologies said it entered into strategic agreements with A&B Company for Portable Neuromodulation Stimulator Therapy in Greater China and Singapore and will undertake development and commercialization responsibilities. Release
> Hong Kong-based XIO has completed a $510 million takeover of surgical, ophthalmological and aesthetic applications firm Lumenis, an Israel-based company. Report
> U.S.-based CardioKinetix received South Korea Ministry of Food and Drug Safety approval for its ParachuteSystem device for heart patient use in first minimally invasive catheter-based treatment to partition the damaged muscle. Release
> Japan's Astellas is ready for more deal making, Reuters reports, after splashing out $300 million to U.S.-based Immunomic Therapeutics for its LAMP-vax platform to treat or prevent allergic diseases this month as it looks to rebuild a drug pipeline in both established and new therapy areas. Report
> South Korean drug companies are cashing in on generics at home, beating out original brands as can be seen in the case of Eli Lilly's ($LLY) Cialis, with 60 domestic firms offering 150 copies within a month of expiry. Report
> Japan's Takeda Pharmaceutical said it will present recent findings for its drug vedolizumab, used to treat ulcerative colitis and Crohn's disease, at industry events in Hawaii and Spain. Release
> Australia's Benitec Biopharma said it has formed a Hepatology Clinical Advisory Board to "serve as a strategic resource" to the company in the development of medicines for Hepatitis B and C. The three-member panel includes: Dr. Geoffrey McMaughan, AW Morrow Professor of Medicine at the Royal Alfred Hospital and the University of Sydney; Dr. Harry Janssen, the Francis Family Chair in Liver Research and head of the liver clinic at the Centenary Institute in Sydney; and Dr. Keyur Patel, associate professor of medicine at the Toronto Western Liver Clinic. Release (PDF)
> DelMar Pharmaceuticals said it has presented clinical data on its drug VAL-083 that show it has "positive potential" as a treatment for ovarian cancer. The data was derived from the company's work with researchers at the MD Anderson Cancer Center. Release
> India's Apollo Health and Lifestyle said it has hired Spark Capital to help sell a 25% stake in the company to raise $78 million to fund its expansion plans. The company is a subsidiary of Apollo Hospitals. Report